{
    "2019-11-06": [
        [
            {
                "time": "2018-11-06",
                "original_text": "格隆汇港股聚焦(11.06)︱港交所前三季EBITDA升3%至96.63亿港元 多家券商10月数据亮眼",
                "features": {
                    "keywords": [
                        "港交所",
                        "EBITDA",
                        "券商",
                        "10月数据"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "国家药监局：政策人才资本都是当前药品创新的利好因素",
                "features": {
                    "keywords": [
                        "国家药监局",
                        "政策",
                        "药品创新",
                        "利好因素"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "一致性评价新进展：这家企业厉害了！",
                "features": {
                    "keywords": [
                        "一致性评价",
                        "企业",
                        "进展"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "11月6日股市预警|8家公司突发利空 34亿资金流出这十股",
                "features": {
                    "keywords": [
                        "股市预警",
                        "利空",
                        "资金流出"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "复星医药：控股子公司用于晚期实体瘤治疗药品获临床试验申请受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "临床试验",
                        "晚期实体瘤"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "复星医药(600196.SH)：ORIN1001片用于晚期实体瘤治疗获临床试验注册审评受理",
                "features": {
                    "keywords": [
                        "复星医药",
                        "ORIN1001片",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "一致性评价铺就中国仿制药提质之路",
                "features": {
                    "keywords": [
                        "一致性评价",
                        "仿制药",
                        "提质"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "169个品种通过一致性评价，有企业过评30个",
                "features": {
                    "keywords": [
                        "一致性评价",
                        "品种",
                        "企业"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-06",
                "original_text": "【晨会聚焦】超配金融板块",
                "features": {
                    "keywords": [
                        "晨会聚焦",
                        "金融板块",
                        "超配"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-11-05",
                "original_text": "【医药-复星医药(600196)】江琦、赵磊：公司点评：Grand计划推进海外上市，生物药、小分子创新持续",
                "features": {
                    "keywords": [
                        "复星医药",
                        "Grand计划",
                        "海外上市",
                        "生物药",
                        "小分子创新"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}